HSV formulation 1 with adjuvant 2

HSV formulation 1 with adjuvant 2 is an investigational **adjuvanted recombinant-protein therapeutic vaccine formulation** within GSK's GSK-3943104 herpes simplex virus targeted-immunotherapy programme. It was evaluated as a two-dose intramuscular regimen in the phase I portion of the TH HSV REC-003 study, including assessment of safety, reactogenicity, and immune responses in healthy adults. The precise HSV antigen composition and identity of \"adjuvant 2\" have not been publicly disclosed. GSK reported that the overall GSK3943104 phase I/II programme did not meet its phase II primary efficacy objective in recurrent genital herpes and would not advance to phase III studies. ([anzctr.org.au](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=21440&isClinicalTrial=True))